Remote Ischemic Conditioning for Intracerebral Hemorrhage (RICH)
Primary Purpose
Intracerebral Hemorrhage
Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
remote ischemic conditioning
Regular treatment
Sponsored by
About this trial
This is an interventional treatment trial for Intracerebral Hemorrhage focused on measuring Spontenous intracerebral hemorrhage, Hemorrhage resolution, Remote ischemic conditioning, Neuroprotection
Eligibility Criteria
Inclusion Criteria:
- Age≥18 and ≤80.
- The diagnosis of ICH is confirmed by brain CT scan.
- Hematoma volume of 10 to 30 ml.
- Glasgow Coma Score (GCS)>8.
- Starting RIC treatment between 24 and 48 hours of ictus.
- Signed and dated informed consented is obtained.
Exclusion Criteria:
- Patients with suspected secondary ICH related to tumor, coagulopathy, ruptured aneurysm or arteriovenous malformation, or venous sinus thrombosis.
- ICH concomitant with subarachnoid hemorrhage or intraventricular hemorrhage. Planned surgical evacuation of hematoma prior to RIC.
- Evidence of significant shift of midline brain structure (> 10 mm) or herniation on brain imaging.
- Known pregnancy (or positive pregnancy test), or breast-feeding.
- Concurrent participation in another research protocol for investigation of another experimental therapy.
- Patients with a pre-existing neurological deficits (modified Ranks scale score >1) or psychiatric disease that would confound the neurological or functional evaluations.
- Life expectancy of less than 90 days due to co-morbid conditions.
- Severe hepatic and renal dysfunction.
- Severe, sustained hypertension (SBP > 180 mmHg or DBP > 110 mmHg).
- Contraindication for remote ischemic conditioning: severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs.
- Any condition which, in the judgment of the investigator, might increase the risk to the patient.
Sites / Locations
- Xuanwu Hospital, Capital Medical University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
RIC group
Control group
Arm Description
RIC treatment and regular treatment.
Regular treatment alone.
Outcomes
Primary Outcome Measures
Incidence of Treatment-Emergent Adverse Events [Safety]
Secondary Outcome Measures
Full Information
NCT ID
NCT03930940
First Posted
April 20, 2019
Last Updated
February 10, 2020
Sponsor
Capital Medical University
Collaborators
Heze Municipal Hospital, The Sixth People's Hosptial of Hengshui, Weihai Municipal Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03930940
Brief Title
Remote Ischemic Conditioning for Intracerebral Hemorrhage
Acronym
RICH
Official Title
Safey and Efficacy of Remote Ischemic Conditioning in Patient With Spontaneous Intracerebral Hemorrhage
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
July 9, 2019 (Actual)
Primary Completion Date
November 17, 2019 (Actual)
Study Completion Date
February 10, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Capital Medical University
Collaborators
Heze Municipal Hospital, The Sixth People's Hosptial of Hengshui, Weihai Municipal Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Spontaneous intracerebral hemorrhage (ICH) results from the rupture of small vessels damaged by chronic hypertension, amyloid angiopathy or other disease. Hematoma volume has been demonstrated to be strongly correlated with the severity of white matter injury and conditions in ICH patients. In the past decades, surgical clot evacuation and stereotactic or endoscopic clot aspiration with thrombolytic drugs have been investigated for the treatment of ICH, however, none of them have been demonstrated to be effective. As such, medical management remains the standard of care for most patients with ICH, leading to ICH as the least treatable form of stroke.
Remote ischemic conditioning (RIC) has been found to have neuroprotective effects by in patients with ischemic stroke. In addition, animal studies show that RIC is safe in ICH model and it could accelerate the absorption of hematoma. Therefore, the investigators plan to undertake this study to evaluate the safety of RIC in patients with ICH, and planned for future study to determine if treatment with RIC can improve the outcome of patients with ICH.
In this study, our main objectives are: 1) to evaluated the safety of RIC, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the preliminary effects of RIC on hematoma absorption and cerebral edema.
The investigators hypothesize that RIC is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with RIC will accelerate the absorption of hematoma and improve patients' functional outcomes. Results of this study can potentially bring into account new means to improve the outcomes of ICH patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intracerebral Hemorrhage
Keywords
Spontenous intracerebral hemorrhage, Hemorrhage resolution, Remote ischemic conditioning, Neuroprotection
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
RIC group
Arm Type
Experimental
Arm Description
RIC treatment and regular treatment.
Arm Title
Control group
Arm Type
Other
Arm Description
Regular treatment alone.
Intervention Type
Device
Intervention Name(s)
remote ischemic conditioning
Intervention Description
RIC is a non-invasive therapy that performed by an electric autocontrol device with cuffs placed on arm and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 4 to 5 times.
Intervention Type
Other
Intervention Name(s)
Regular treatment
Intervention Description
Regular treatment is based on associated guidelines for ICH.
Primary Outcome Measure Information:
Title
Incidence of Treatment-Emergent Adverse Events [Safety]
Time Frame
7 days.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age≥18 and ≤80.
The diagnosis of ICH is confirmed by brain CT scan.
Hematoma volume of 10 to 30 ml.
Glasgow Coma Score (GCS)>8.
Starting RIC treatment between 24 and 48 hours of ictus.
Signed and dated informed consented is obtained.
Exclusion Criteria:
Patients with suspected secondary ICH related to tumor, coagulopathy, ruptured aneurysm or arteriovenous malformation, or venous sinus thrombosis.
ICH concomitant with subarachnoid hemorrhage or intraventricular hemorrhage. Planned surgical evacuation of hematoma prior to RIC.
Evidence of significant shift of midline brain structure (> 10 mm) or herniation on brain imaging.
Known pregnancy (or positive pregnancy test), or breast-feeding.
Concurrent participation in another research protocol for investigation of another experimental therapy.
Patients with a pre-existing neurological deficits (modified Ranks scale score >1) or psychiatric disease that would confound the neurological or functional evaluations.
Life expectancy of less than 90 days due to co-morbid conditions.
Severe hepatic and renal dysfunction.
Severe, sustained hypertension (SBP > 180 mmHg or DBP > 110 mmHg).
Contraindication for remote ischemic conditioning: severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs.
Any condition which, in the judgment of the investigator, might increase the risk to the patient.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xunming Ji, MD, PhD
Organizational Affiliation
Xuanwu Hospital, Capital Medical Univeristy
Official's Role
Principal Investigator
Facility Information:
Facility Name
Xuanwu Hospital, Capital Medical University
City
Beijing
ZIP/Postal Code
100053
Country
China
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30190288
Citation
Vaibhav K, Braun M, Khan MB, Fatima S, Saad N, Shankar A, Khan ZT, Harris RBS, Yang Q, Huo Y, Arbab AS, Giri S, Alleyne CH Jr, Vender JR, Hess DC, Baban B, Hoda MN, Dhandapani KM. Remote ischemic post-conditioning promotes hematoma resolution via AMPK-dependent immune regulation. J Exp Med. 2018 Oct 1;215(10):2636-2654. doi: 10.1084/jem.20171905. Epub 2018 Sep 6.
Results Reference
background
PubMed Identifier
28174194
Citation
Zhao W, Meng R, Ma C, Hou B, Jiao L, Zhu F, Wu W, Shi J, Duan Y, Zhang R, Zhang J, Sun Y, Zhang H, Ling F, Wang Y, Feng W, Ding Y, Ovbiagele B, Ji X. Safety and Efficacy of Remote Ischemic Preconditioning in Patients With Severe Carotid Artery Stenosis Before Carotid Artery Stenting: A Proof-of-Concept, Randomized Controlled Trial. Circulation. 2017 Apr 4;135(14):1325-1335. doi: 10.1161/CIRCULATIONAHA.116.024807. Epub 2017 Feb 7.
Results Reference
background
PubMed Identifier
29974450
Citation
Zhao W, Zhang J, Sadowsky MG, Meng R, Ding Y, Ji X. Remote ischaemic conditioning for preventing and treating ischaemic stroke. Cochrane Database Syst Rev. 2018 Jul 5;7(7):CD012503. doi: 10.1002/14651858.CD012503.pub2.
Results Reference
background
PubMed Identifier
30009202
Citation
Zhao W, Che R, Li S, Ren C, Li C, Wu C, Lu H, Chen J, Duan J, Meng R, Ji X. Remote ischemic conditioning for acute stroke patients treated with thrombectomy. Ann Clin Transl Neurol. 2018 Jun 6;5(7):850-856. doi: 10.1002/acn3.588. eCollection 2018 Jul.
Results Reference
background
PubMed Identifier
30656197
Citation
Zhao W, Li S, Ren C, Meng R, Jin K, Ji X. Remote ischemic conditioning for stroke: clinical data, challenges, and future directions. Ann Clin Transl Neurol. 2018 Nov 15;6(1):186-196. doi: 10.1002/acn3.691. eCollection 2019 Jan.
Results Reference
background
PubMed Identifier
33739197
Citation
Zhao W, Jiang F, Li S, Liu G, Wu C, Wang Y, Ren C, Zhang J, Gu F, Zhang Q, Gao X, Gao Z, Song H, Ma Q, Ding Y, Ji X; RICH-1 Investigators. Safety and efficacy of remote ischemic conditioning for the treatment of intracerebral hemorrhage: A proof-of-concept randomized controlled trial. Int J Stroke. 2022 Apr;17(4):425-433. doi: 10.1177/17474930211006580. Epub 2021 Apr 7.
Results Reference
derived
PubMed Identifier
32411082
Citation
Zhao W, Jiang F, Li S, Wu C, Gu F, Zhang Q, Gao X, Gao Z, Song H, Wang Y, Ji X; RICH-1 Investigators. Remote Ischemic Conditioning for Intracerebral Hemorrhage (RICH-1): Rationale and Study Protocol for a Pilot Open-Label Randomized Controlled Trial. Front Neurol. 2020 Apr 28;11:313. doi: 10.3389/fneur.2020.00313. eCollection 2020.
Results Reference
derived
Learn more about this trial
Remote Ischemic Conditioning for Intracerebral Hemorrhage
We'll reach out to this number within 24 hrs